DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Anacetrapib is an investigational drug.
There have been 14 clinical trials for Anacetrapib. The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2008.
The most common disease conditions in clinical trials are Dyslipidemias, Hypercholesterolemia, and Hyperlipoproteinemia Type II. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., Cambridge University Hospitals NHS Foundation Trust, and British Heart Foundation Cambridge Centre of Excellence.
Recent Clinical Trials for Anacetrapib
|The Effect of Anacetrapib on Vascular Function and Arterial Stiffness||British Heart Foundation Cambridge Centre of Excellence||N/A|
|The Effect of Anacetrapib on Vascular Function and Arterial Stiffness||Cambridge University Hospitals NHS Foundation Trust||N/A|
|Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)||Merck Sharp & Dohme Corp.||Phase 3|